Skip to main content

Domainex

  • About
    • About
    • Case Studies
    • Testimonials
    • Awards
    • Board members
    • Investors
    • Management team
    • Contact us
  • Services
    • Offerings
      • Integrated Drug Discovery Services
      • Protein Expression and Purification Services
      • X-ray crystallography
      • Assay Development
      • Biophysical Assays
      • Biochemical Assays
      • Synthetic Chemistry
      • Virtual screening
      • Fragment and Compound Screening
      • Computational Chemistry
      • Medicinal Chemistry
      • Cell Based Assays
      • ADME and Bioanalytical Sciences
      • Analytical Chemistry
    • Research Phases
      • Hit Identification
      • Hit to Lead
      • Lead Optimisation
    • Therapeutic Areas
      • Oncology
      • Immuno-Oncology
      • Cardiovascular
      • Respiratory
      • Anti-infectives
      • Inflammatory diseases
      • CNS Drug Discovery
    • Target Classes
      • Kinases
      • GPCRs
      • Proteases
      • Methyltransferases
      • Ion Channels
      • Protein-Protein Interactions
    • Approaches & Techniques
      • CDH (Target Gene Fragmentation)
      • PoLiPa (Membrane Protein Solubilisation)
      • LeadBuilder
      • FragmentBuilder
      • Fragment Based Drug Discovery (FBDD)
      • Structure Based Drug Design (SBDD)
      • Differential Scanning Fluorimetry (DSF) and nanoDSF Services
      • Grating-Coupled Interferometry
      • High Throughput Screening
      • MicroScale Thermophoresis (MST) Services
      • Targeted Protein Degradation
  • Library
    • Articles
    • Brochures
    • Newsletters
    • Posters
    • Presentations & Videos
    • Publications
    • White Papers
  • News & Events
  • Careers
  • English
  • French
  • Spanish
  • German
  • Italian
  • Japanese
  • Dutch
Enquire

Library

Breadcrumb

  1. Home
  2. Library

Domainex Q2 2022 Newsletter - Springing into the new season

Newsletters

Cambridge Independent | Domainex expands bioanalytic chemistry services with £1m Waters investment

Articles

Manufacturing Chemist | Domainex acquires more than £1m of Waters equipment

Articles

Domainex Q1 2022 Newsletter - Exciting collaborations to kick off 2022

Newsletters

Manufacturing Chemist | Parkinson’s UK and Domainex collaborate on inflammation therapy

Articles

Manufacturing Chemist | Queen’s University Belfast enters FLIP inhibitor collaboration

Articles

“Scar-in-a-jar”: in vitro assay for the quantification of key markers of fibrosis

White Papers

The discovery of novel gold(I) complexes for the treatment of Gram-positive and Gram-negative bacterial infections

Posters

Covalent Fragment Screen using QToF analysis

Posters

"Scar-in-a-jar": in vitro assay for the quantification of key markers of fibrosis

Posters

Domainex Q3 2021 Newsletter - Celebrating 20 years in Drug Discovery

Newsletters

Cell Accumulation and Fraction Unbound bridge the gap between enzyme and cellular assay disconnects

White Papers

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Next page Next ›
  • Last page Last »

Start your next project with Domainex

Contact one of our experts today
Domainex
  • About
    • About
    • Case Studies
    • Testimonials
    • Awards
    • Board members
    • Investors
    • Management team
    • Contact us
  • Services
    • Offerings
      • Integrated Drug Discovery Services
      • Protein Expression and Purification Services
      • X-ray crystallography
      • Assay Development
      • Biophysical Assays
      • Biochemical Assays
      • Synthetic Chemistry
      • Virtual screening
      • Fragment and Compound Screening
      • Computational Chemistry
      • Medicinal Chemistry
      • Cell Based Assays
      • ADME and Bioanalytical Sciences
      • Analytical Chemistry
    • Research Phases
      • Hit Identification
      • Hit to Lead
      • Lead Optimisation
    • Therapeutic Areas
      • Oncology
      • Immuno-Oncology
      • Cardiovascular
      • Respiratory
      • Anti-infectives
      • Inflammatory diseases
      • CNS Drug Discovery
    • Target Classes
      • Kinases
      • GPCRs
      • Proteases
      • Methyltransferases
      • Ion Channels
      • Protein-Protein Interactions
    • Approaches & Techniques
      • CDH (Target Gene Fragmentation)
      • PoLiPa (Membrane Protein Solubilisation)
      • LeadBuilder
      • FragmentBuilder
      • Fragment Based Drug Discovery (FBDD)
      • Structure Based Drug Design (SBDD)
      • Differential Scanning Fluorimetry (DSF) and nanoDSF Services
      • Grating-Coupled Interferometry
      • High Throughput Screening
      • MicroScale Thermophoresis (MST) Services
      • Targeted Protein Degradation
  • Library
    • Articles
    • Brochures
    • Newsletters
    • Posters
    • Presentations & Videos
    • Publications
    • White Papers
  • News & Events
  • Careers
COVID-19

+44 (0) 1223 743170 enquiries@domainex.co.uk

Offerings

  • Protein Expression and Purification Services
  • X-Ray crystallography
  • Biochemical Assays
  • Biophysical Assays
  • Assay Development
  • Fragment and Compound Screening
  • Cell Based Assays
  • Medicinal Chemistry
  • Synthetic Chemistry
  • Computational Chemistry
  • Analytical Chemistry
  • ADME and Bioanalytical Sciences

Research Phases

  • Lead Optimisation
  • Hit to Lead
  • Hit Identification

Therapeutic Areas

  • Oncology
  • Immuno-Oncology
  • Cardiovascular
  • Respiratory Disease
  • Anti-infectives
  • Inflammatory diseases
  • CNS Drug Discovery

Target Classes

  • Kinases
  • GPCRs
  • Proteases
  • Protein Methyltransferases
  • Ion Channels
  • Protein-Protein Interactions

Approaches & Techniques

  • CDH (Target Gene Fragmentation)
  • LeadBuilder – Virtual Screening
  • FragmentBuilder: Fragment-Based Drug Discovery and Design
  • Innovative Polymer Lipid Particle (PoLiPa) Technology
  • Structure Based Drug Design (SBDD)
  • Ligand binding assays by Surface Plasmon Resonance (SPR) and/or Grating-Coupled Interferometry (GCI)
  • MicroScale Thermophoresis (MST) Services
  • Differential Scanning Fluorimetry (DSF) and nanoDSF Services
  • High Throughput Screening
  • Targeted Protein Degradation

Domainex is a registered company (number 4336899)

Site and its contents Copyright © Domainex 2022. All rights reserved.